Compare MMYT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | ORKA |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | India | United States |
| Employees | N/A | 68 |
| Industry | Transportation Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.5B |
| IPO Year | 2010 | N/A |
| Metric | MMYT | ORKA |
|---|---|---|
| Price | $53.22 | $91.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $101.00 | $92.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.83 | N/A |
| Revenue Next Year | $17.24 | N/A |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $12.84 |
| 52 Week High | $104.99 | $97.78 |
| Indicator | MMYT | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 64.62 |
| Support Level | $53.09 | $27.81 |
| Resistance Level | $59.43 | $97.78 |
| Average True Range (ATR) | 2.52 | 5.43 |
| MACD | -0.63 | -0.34 |
| Stochastic Oscillator | 21.13 | 77.49 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.